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Abstract
The Rare Disease and Orphan Drug Act (the Act) was enacted in 2000 in Taiwan for the facilitation of the research,
development, and accessibility of orphan drugs and special nutritional foods; for the prevention and early diagnosis of
rare diseases; and for providing intensive care for patients with rare diseases. The aim was to investigate the impact of
the Act on the availability and use of orphan drugs in Taiwan in the hope of identifying the remaining challenges and
possible solutions to assist future policy making, which may be applicable in other countries as well. The information
and statistics for rare diseases and orphan drugs retrieved from the ofﬁcial annual reports and documents were analyzed.
There were 225 diseases recognized as rare diseases, and one-third (75/225) of them were congenital metabolic disorders.
Among the 110 designated orphan drugs that could apply for listing in the National Health Insurance (NHI) Pharmaceutical Beneﬁts and Reimbursement Scheme, approximately half (62/110) of them were granted marketing authorization. While the NHI program compulsory for all citizens increased patient accessibility to orphan drugs, the rapidly
increasing economic burden became an urgent issue for the government. Emerging gene therapies may be the solution to
unmet medical needs and also a ﬁnancial obstacle to tackle. The Act increased the availability of orphan drugs while the
NHI system facilitated patient access, which beneﬁted many patients with rare diseases in Taiwan. However, the soaring
economic burden was noticed and was anticipated to aggravate. More communication and cooperation between
stakeholders is critical in ﬁnding solutions for the long-term sustainability of the NHI system.
Keywords: Orphan drugs, Regulation, Reimbursement, Taiwan

1. Introduction

R

are diseases, as suggested by the term, are
diseases affecting limited patient populations
[1e6]. Although the terminology was not harmonized internationally, rare diseases are often
serious, mostly genetically based, and can be lifethreatening [1e3]. Many patients with rare diseases
suffer from a lack of available treatment while some
of them may even be undiagnosed [2,3]. In view of
this, the Orphan Drug Act was passed in 1983 in the
United States (US), and related legislations have
been established worldwide [2e6]. In Taiwan, The
Rare Disease and Orphan Drug Act (the Act) was

enacted in 2000 for the facilitation of the research,
development, and accessibility of orphan drugs and
special nutritional foods; for the prevention and
early diagnosis of rare diseases; and for providing
intensive care for patients with rare diseases [7]. The
Act deﬁned the term “rare diseases” as “diseases
with a prevalence rate lower than the standard
announced by the central competent authority
(Ministry of Health and Welfare, MOHW); or diseases recognized through review by the Review
Committee speciﬁed in Article 4 of this Act, and
designated and publicly announced by the central
competent authority under special circumstances”
[7]. The current standard for the prevalence rate is 1
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per 10,000, and the recognition also involves considerations regarding heredity, the difﬁculties in
diagnosis and treatment, and the exclusion of diseases/harm due to external or acquired factors and
cancers [8,9].
In Taiwan, the National Health Insurance (NHI)
program is a system of universal health coverage
launched in 1995 and is compulsory for all citizens
[10]. According to the National Health Insurance Act
[11], “in case the beneﬁciaries encounter illness,
injury, or maternity, the contracted medical care
institutions shall provide medical services.” Then,
“the contracted medical care institutions shall
declare to the Insurer (NHIA, MOHW) the points of
the medical services rendered and expense of drugs,
based on the Fee Schedule and Reference List for
Medical Services and the Reference List for Drugs.”
For patients with rare diseases, the copayment for
the treatment related to rare diseases is exempted so
as to reduce patients’ ﬁnancial burdens [12]. Since
2009, a speciﬁed proportion of the tobacco health
and welfare surcharge has been utilized for the
treatment of rare diseases [13].
According to the Act, the designation of orphan
drugs is reviewed by the Review Committee and
then announced by the central competent authority.
These orphan drugs could apply for listing in the
NHI Pharmaceutical Beneﬁts and Reimbursement
Scheme after obtaining approval through the
registration process or speciﬁc permission to
import; within ten years from the market approval,
the central competent authority shall not accept
applications for registration of pharmaceuticals of
the same kind. In addition to the aforementioned
incentive, the central competent authority should
provide funding support to encourage research
related to the prevention and control of rare diseases [7]. Moreover, the application fees for marketing registration and related processes were
reduced [14,15]. For example, the application fee for
the registration of a new orphan drug is approximately US$341, in contrast to US$51181 for that of a
nonorphan new chemical entity based on the exchange rate (29.308) announced on September 16,
2020 by the Central Bank of the Republic of China
(Taiwan) [14e16]. Sponsors can also apply for priority review and the accelerated approval pathway
based on the surrogate endpoint for applications of
new orphan drugs, and scientiﬁc advice is also
available [17,18].
The implementation of the Act and related regulations at the government level is mainly achieved
by the cooperation of three administrative agencies
in the MOHW, including the Health Promotion
Administration (HPA), the Food and Drug

Administration (FDA), and the National Health Insurance Administration (NHIA) [19e21]. For
example, the recognition of rare diseases and regular reviews of the qualiﬁcations of designated institutions for genetic and rare diseases are governed
by the HPA [19]. A rare disease special nutritional
food and drug logistic center was initiated to store
and supply special nutritional foods essential for the
maintenance of life and emergency drugs for patients with rare diseases [19]. Moreover, the HPA
also provides medical subsidies for rare diseases not
covered by the NHI; subsidies for programs related
to the prevention, control, and advocacy of rare
diseases; and care assistance to patients and their
families through commissioned institutions [19]. In
addition, the designation of orphan drugs, the
approval for the marketing authorization applications of orphan drugs, and the compilation of the
annual reports for drugs to which the Act is applicable are conducted by the Taiwan FDA [20]. The
NHIA is responsible for managing health insurance
affairs, including but not limited to the determination of the reimbursement prices for the designated/
approved orphan drugs, while the NHI covers most
of the medical expense for patients with rare diseases [21].
Similar to the situations in other countries
worldwide, patient advocacy groups in Taiwan also
play important roles in making rare diseases a priority for health policy [6,22]. For example, the
Taiwan Foundation for Rare Disorders, founded in
1999, actively promoted the adoption of the Act and
is continually devoted to the improvement of the
lives of patients with rare diseases through various
activities [22]. To date, it has been 20 years since the
enactment of the Act [7]. The aim of the present
study was to investigate the impact of the implementation of the Act on the availability of orphan
drugs in Taiwan through the study of available
orphan drugs, their utilization, and the associated
economic burden in the hope of identifying the
remaining challenges and possible solutions to
assist future policy making, which may be applicable in other countries as well.

2. Methods
The information and statistics for rare diseases
and orphan drugs were retrieved from the annual
reports and documents announced and/or published by the MOHW, Taiwan, which are publicly
available on ofﬁcial websites (last accessed
September 16, 2020) [7,9e15,17e21,23e30]. Based on
the Act [7], “when there are difﬁculties in
manufacturing or importing nonorphan drugs in

accordance with the provisions of the Pharmaceutical Affairs Act, and said drugs are reviewed by the
Review Committee and determined to be beneﬁcial
for the treatment of speciﬁc diseases, provisions in
this Act regarding registration, market approval and
ad hoc application may be applied”. These drugs
were classiﬁed as drugs that were “difﬁcult to
obtain”. Therefore, in the present study, these drugs
were included unless stated otherwise. Drugs with
the same active pharmaceutical ingredient(s) were
regarded as the same drug despite differences in
unit doses (strengths) and/or dosage forms. If a drug
had more than one unit dose (strength)/dosage
form, the earliest time for designation and/or
approval for marketing authorization was recorded.
The drug Cholbam (cholic acid) is indicated for (1)
treatment of bile acid synthesis disorders due to
single enzyme defects; (2) adjunctive treatment of
peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications
from decreased fat-soluble vitamin absorption [28].
Herein, only the ﬁrst indication is included in the
calculation of the number of the orphan drugs. The
estimation of the evolution of annual NHI expenditures on speciﬁc drugs was calculated using the
amounts of the drugs used stated in the annual
report [20] multiplied by the unit prices announced
by the NHIA in the same year [25]. If there was a
change in a reimbursement price within the year of
interest, the highest price was used for the estimation. The total NHI expenditures for orphan drugs,
the total amounts from the subsidies from the tobacco health and welfare surcharge, and the
numbers of patients suffering from rare diseases
from 2009 to 2018 were collected from the public
document released by the NHIA [13]. The conversion of New Taiwan dollars to US dollars was based
on the 2016 exchange rate (32.3180) obtained from
the Central Bank of the Republic of China (Taiwan)
[31] and the data were adjusted using the annual
consumer price index - medicines & health food
(base: 2016 ¼ 100) collected from the AREMOS
Taiwan Economic Statistical Databanks for inﬂation
unless stated otherwise [32]. Microsoft Excel 2016
was utilized for the analysis and the preparation of
the table and ﬁgures.
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orphan drugs, including 29 drugs classiﬁed as
“difﬁcult to obtain” [20,23,24]. The top three types of
these 110 orphan drugs classiﬁed by the Anatomical
Therapeutic Chemical (ATC) classiﬁcation [33]
include drugs for alimentary tract and metabolism
(A, 30 drugs), antineoplastic and immunomodulating agents (L, 18 drugs), and drugs for blood and
blood forming organs (B, 14 drugs). The categories
of rare diseases classiﬁed in the annual report and
the distribution of currently available orphan drugs
excluding 29 “difﬁcult to obtain” drugs are collectively displayed in Table 1. One-third (75/225) of
recognized rare diseases were congenital metabolic
disorders, and there were approximately half of
orphan drugs excluding those classiﬁed as “difﬁcult
to obtain” (35/81) indicated for treating patients with
these diseases. Among 225 rare diseases, multiple
sclerosis had the highest number (11) of available
drugs, followed by idiopathic or heritable pulmonary arterial hypertension (IPAH or HPAH) with
nine designated orphan drugs. Nonetheless, there
were still many rare diseases without available
drugs, such as those classiﬁed as kidney and urinary
system disorders, muscle disorders, connective tissue disorders, congenital malformation syndromes,
and other unclassiﬁed diseases or diseases due to
unknown causes.
Among the 110 designated orphan drugs, 56% (62/
110) were granted marketing authorization,
including 14 “difﬁcult to obtain” drugs. Among the
62 drugs with marketing authorization, 23% (14/62)
involved at least one manufacturer in Taiwan.
Except for one “difﬁcult to obtain” drug for which
the date for authorization was earlier than the date
for designation, the average time from designation
to approval for 13 “difﬁcult to obtain” drugs was
1887 days (Fig. 1a). Similarly, except for two drugs
for which the dates for authorization were earlier
than the dates for designation, the average time
from designation to approval for 46 orphan drugs
not including “difﬁcult to obtain” drugs was 1621
days (Fig. 1b). There were 11 orphan drugs with
more than one dosage form, including one “difﬁcult
to obtain” drug. Thirty-two drugs had more than
one unit dose, including four “difﬁcult to obtain”
drugs.
3.2. Evolution of the utilization pattern

3. Results
3.1. Characteristics of the rare diseases and the
orphan drugs currently available in Taiwan
Currently, there are 225 diseases recognized as
rare diseases; and there are 110 available designated

The top three most commonly used orphan drugs
from 2001 to 2018 is shown in Fig. 2. Herein, drugs
classiﬁed as orphan drugs including those listed as
“difﬁcult to obtain” to which the Act could be
applied for the respective year were included.
Except for 2007, the data for the amount of drugs

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:717e725

720

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:717e725

ORIGINAL ARTICLE

Table 1. Categories of rare diseases and the distribution of currently available orphan drugs.
Category of rare diseases

Number of
rare diseases

(%)

Number of
orphan drugsa

(%)

Congenital metabolic disorders
Brain and nervous system disorders
Respiratory and circulatory system disorders
Digestive system disorders
Kidney and urinary system disorders
Skin disorders
Muscle disorders
Bone and cartilage disorders
Connective tissue disorders
Blood disorders
Immune system disorders
Endocrine disorders
Congenital malformation syndromes
Chromosomal abnormalities
Other unclassiﬁed or unknown causes

75
26
8
5
3
12
15
9
1
5
10
15
27
9
5

33.3
11.6
3.6
2.2
1.3
5.3
6.7
4.0
0.4
2.2
4.4
6.7
12.0
4.0
2.2

35
19
10
2
0
1
0
1
0
3
3
6
0
1
0

43.2
23.5
12.3
2.5
0.0
1.2
0.0
1.2
0.0
3.7
3.7
7.4
0.0
1.2
0.0

These orphan drugs did not include “difﬁcult to obtain” drugs. Drugs with the same active pharmaceutical ingredient(s) were
regarded as the same drug despite differences in unit doses (strengths) and/or dosage forms. The drug Cholbam (cholic acid) is indicated for (1) treatment of bile acid synthesis disorders due to single enzyme defects; (2) adjunctive treatment of peroxisomal disorders
including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from
decreased fat-soluble vitamin absorption [28]. Herein, only the ﬁrst indication is included in the calculation of the number of the orphan
drugs.
a

Fig. 1. The distribution of the time intervals (days) from designation to approval for (a) “difﬁcult to obtain” drugs except for one drug for which the
date for authorization was earlier than the date for designation or (b) orphan drugs not including “difﬁcult to obtain” drugs except for two drugs for
which the dates for authorization were earlier than the dates for designation.

used were available in the annual reports [20] from
2001 to 2018 (Fig. 2). Among these commonly used
orphan drugs deﬁned by the amount of drugs used
each year (Fig. 2a), the “difﬁcult to obtain” drug
containing anagrelide (anagrelide hydrochloride
monohydrate), a platelet reducing agent used to
treat essential thrombocythemia, ranked as the top
drug in 2004, in 2006, and from 2008 to 2018.
Considering the number of patients using the drugs,
data were available in the annual reports [20] from
2001 to 2018 except 2007 (Fig. 2b). A drug containing
anagrelide also ranked as the top drug in 2004 and
from 2008 to 2014.

Orphan drugs including those classiﬁed as “difﬁcult to obtain” with the top three highest annual
NHI expenditures from 2001 to 2018 except 2007
(data not available in the annual reports [20]) are
shown in Fig. 3. Among these 12 drugs, half are
enzyme replacement therapies. For example, imiglucerase for Gaucher disease type 1 was ranked as
the top drug from 2001 to 2006 and third in 2010.
Agalsidase alfa for Fabry disease ranked as the top
drug from 2011 to 2018. A similar drug for Fabry
disease, agalsidase beta, ranked second in 2002,
from 2004 to 2006, and in 2009 and third in 2003,
2008, 2017, and 2018. Another two drugs that once
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Fig. 2. The top three most commonly used orphan drugs deﬁned by (a) the amount of drugs used or (b) the number of patients using the drugs each
year from 2001 to 2018 except for 2007 for which data were not available. Drugs with the same active pharmaceutical ingredient(s) were regarded as
the same drug despite differences in unit doses (strengths) and/or dosage forms. The amount of drugs was calculated by the number of dosage units
except that the amount of phosphate solution was calculated in “milliliters”.

Fig. 3. The top three most costly orphan drugs deﬁned by the annual National Health Insurance (NHI) expenditures from 2001 to 2018 except for 2007
for which data were not available. The conversion of New Taiwan dollars to US dollars was based on the 2016 exchange rate (32.3180) obtained from
the Central Bank of the Republic of China (Taiwan) [31] and the data were adjusted with the annual consumer price index - medicines & health food
(base: 2016 ¼ 100) collected from the AREMOS Taiwan Economic Statistical Databanks for inﬂation [32]. Drugs with the same active pharmaceutical ingredient(s) were regarded as the same drug despite differences in unit doses (strengths) and/or dosage forms.

ranked at the top, galsulfase and alglucosidase alfa,
were also enzyme replacement therapies indicated
for use in patients with mucopolysaccharidosis VI
and Pompe disease, respectively. Furthermore,
idursulfase for Hunter syndrome (mucopolysaccharidosis II, MPS II) ranked third from 2011 to
2013. Among the drugs included in Figs. 2 and 3, no
drug was removed from the orphan drug list except
aldesleukin, which was no longer classiﬁed as an
orphan drug in August, 2002.
3.3. Economic burden
The total NHI expenditures for orphan drugs, the
total amounts of the subsidies from the tobacco
health and welfare surcharge, and the numbers of
patients suffering from rare diseases from 2009 to
2018 are collectively shown in Fig. 4 [13]. As the total
NHI expenditures for orphan drugs grow rapidly,
the allocation of resources becomes an increasingly
important issue for the government. For example,
the recent total expenditures for orphan drugs

accounted for 2.7%, 2.9%, and 3.0% of the total NHI
expenditures for drugs in 2016, 2017, and 2018,
respectively [26]. However, the numbers of patients
with rare diseases accounted for 0.034%, 0.035%,
and 0.037% of the total beneﬁciaries including the
insured and his/her dependents, respectively
[26,27]. The average drug expenditures per patient
with a rare disease was thus unproportionally high,
which remains an issue vigorously debated [34].
The economic challenges could be further aggravated by the emergence of expensive innovative
therapies. For example, nusinersen (Spinraza®) is
an antisense oligonucleotide, an orphan drug
designated in 2018 and approved in 2019 for treating
speciﬁc types of patients with spinal muscular atrophy (SMA) [20,24,28]. The tentative reimbursement price is US$82764 per vial based on the
exchange rate (29.612) announced by the Central
Bank of the Republic of China (Taiwan) on July 1,
2020, the effective date of the price [16,30]. There are
restrictions on the age of patients and the detection
method for the genetic mutation for the
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Fig. 4. The total National Health Insurance (NHI) expenditures for orphan drugs, the total amounts of the subsidies from the tobacco health and
welfare surcharge, and the numbers of patients suffering from rare diseases from 2009 to 2018. The conversion of New Taiwan dollars to US dollars
was based on the 2016 exchange rate (32.3180) obtained from the Central Bank of the Republic of China (Taiwan) [31] and the data were adjusted
with the annual consumer price index - medicines & health food (base: 2016 ¼ 100) collected from the AREMOS Taiwan Economic Statistical
Databanks for inﬂation [32].

reimbursement [30]. In addition, the effectiveness of
the treatment should be evaluated and conﬁrmed or
the payment should be discontinued [30]. Despite
these restrictions, the huge impact on the budget is
foreseeable and requires further observation.

4. Discussion
Despite the similarity in the purpose of the enactment of the law related to orphan drugs, the details
and measures varied among countries. The number
of rare diseases recognized in Taiwan (225) was
relatively low in comparison with those in the EU and
the US with thousands of rare diseases, which could
be related to different deﬁnitions applied, varied
epidemiology, and disparities in the framework of
the reimbursement system [1]. For example, cancers
were excluded from being recognized as rare diseases in Taiwan [8,9] while drugs for rare cancers
could be categorized as orphan drugs in both the EU
and the US [2,35]. The enactment of the law greatly
improved the care for patients with rare diseases,
enhanced the research and development of orphan
drugs in Taiwan, and increased the availability of
orphan drugs in Taiwan. However, a relatively large
proportion of rare diseases recognized still lack
effective treatments (Table 1). More research and
development are needed. To expedite patient access
to orphan drugs, the designated orphan drugs could
apply for listing in the NHI Pharmaceutical Beneﬁts
and Reimbursement Scheme after obtaining speciﬁc
permission to import [7]. However, since the drugs
would be administered to patients, the criteria for
designation of these orphan drugs were largely
different from and much stricter than those designed
for facilitating the development process of the potential orphan drugs in the EU and the US [5]. In
order to promote progress in developing orphan
drugs, the Taiwan FDA announced the Directions for
Applications for Recognition of Orphan Drugs in

Development in 2018 in which the purpose of
recognition resembles that of the designations in the
EU and the US [36]. In addition, in the past, as
mentioned earlier, the application for marketing
authorization was not required for reimbursement
[7]. The results demonstrated that among the 110
designated orphan drugs, only 56% (62/110) were
granted marketing authorization. In order to urge
sponsors to proceed with the application process for
marketing authorization, the “Regulations for National Health Insurance Pharmaceutical Beneﬁts and
Reimbursement Scheme” was amended in 2016 [37].
The designated orphan drugs listed in the NHI
Pharmaceutical Beneﬁts and Reimbursement
Scheme without being granted marketing authorization should apply for marketing authorization
within three years [37]. Although the designated
orphan drugs approved by the US or the EU could be
exempted from this requirement, the amounts to be
paid for these drugs would be reduced annually [37].
The trends of the research and development of
orphan drugs after the implementation of the aforementioned measures are worth further observation.
While the utilization of drugs may be related to
the number of patients with the diseases and the
dosage and administration pattern depending on
the drugs and the conditions of patients, the results
(Fig. 2) suggested that in certain years, some drugs,
such as phosphate solution, levocarnitine, anagrelide, thalidomide, and sildenaﬁl, with the top
three largest amounts of drugs used were also those
with the top three highest numbers of patients using
the drugs. However, the top three most commonly
used orphan drugs deﬁned by the amount of drugs
used and the number of patients using the drug
were seldom the drugs with the top three highest
NHI expenditures (Figs. 2 and 3). Only sodium
phenylbutyrate and interferon beta-1a could be
found simultaneously in both Figs. 2 and 3. The
drugs with the top three highest NHI expenditures

were more often associated with higher unit prices.
For example, imiglucerase (2001e2006), agalsidase
beta (2002e2006, 2008, 2009, 2017, and 2018), agalsidase alfa (2011) and eculizumab (2014e2016) were
the drugs with the top three highest unit prices and
annual NHI expenditures simultaneously in the
respective years stated above.
While the marketing approval of orphan drugs
does not assure affordability for patients [38], the
NHI program in Taiwan [10] signiﬁcantly lowers the
barriers to patient access. The total NHI expenditures for orphan drugs was found to be unproportionally high and rapidly increasing. Hsu et al. [39]
demonstrated similar ﬁndings utilizing rare diseaserelated claims data from 2003 to 2014 from the National Health Insurance Research Database in
Taiwan. They also found an increasing trend of the
related economic burden [39]. Considering the economic challenges, in addition to the aforementioned
nusinersen (Spinraza®), patisiran (Onpattro®) and
onasemnogene abeparvovec (Zolgensma®) are also
worth special attention due to the anticipated high
price [40]. Onasemnogene abeparvovec, a gene
therapy, was designated in 2020 for speciﬁc types of
patients with SMA [24,40]. SMA affected 497 patients
in Taiwan as of August 31, 2020, and 82 patients with
SMA died as of June 30, 2020 [29]. Patisiran, a targeted RNA-based therapy, was designated in 2019
for speciﬁc groups of patients with familial amyloidotic polyneuropathy (FAP) [20]. FAP affected 166
patients in Taiwan as of August 31, 2020, and 59 of
these patients died as of June 30, 2020 [29]. As
mentioned earlier, in Taiwan, the recognition of rare
diseases involves considerations regarding heredity
[8,9], while approximately 80% of rare diseases in the
US was related to a single-gene defect [41]. While
gene therapies bring hope of curing diseases that
were managed chronically in the past, their
extremely high costs would have large impacts on
the health care system, which is a worldwide concern
[42,43].
For these innovative therapies including but not
limited to gene therapies, uncertainty of the clinical
beneﬁts is another issue further complicating the
problem of the economic impact [42,43]. To reduce
the budget impact and increase the early accessibility of these innovative drugs in Taiwan, the
“Regulations for National Health Insurance Pharmaceutical Beneﬁts and Reimbursement Scheme”
was amended in 2018 to introduce the risk-sharing
approach [37]. In addition to the original price-volume agreements, other agreements such as
outcome-based and ﬁnance-based agreements were
incorporated [37]. Therefore, the reimbursement
would be linked to the clinical outcome or ﬁnancial
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status, and the manufacturer would be more
involved and share the risk of the use of these highly
innovative therapies with extremely high costs
[37,43]. Whether the approach would be a long-term
solution for the upcoming challenges of orphan
drugs remains an issue to be closely monitored. The
success and sustainability of the framework and the
NHI system require more communication and
cooperation between all stakeholders.

5. Conclusions
The present study demonstrated that the implementation of the Act and the establishment of the
related regulatory framework increased the availability of orphan drugs. Meanwhile, the NHI program compulsory for all citizens increased patient
accessibility to orphan drugs. The aforementioned
frameworks beneﬁted many patients with rare diseases in Taiwan. Nonetheless, the results also
revealed the need to promote the research and
development of orphan drugs for treating those
diseases without effective treatments and the upcoming challenges posed by the rapidly increasing
economic burden. Emerging gene therapies may
serve as both a solution to unmet medical needs and
a ﬁnancial obstacle to tackle. More communication
and cooperation between stakeholders would be
critical in ﬁnding solutions for the long-term sustainability of the NHI system.
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